These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

420 related items for PubMed ID: 26720632

  • 1. Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy.
    Sun M, Choueiri TK, Hamnvik OP, Preston MA, De Velasco G, Jiang W, Loeb S, Nguyen PL, Trinh QD.
    JAMA Oncol; 2016 Apr; 2(4):500-7. PubMed ID: 26720632
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism.
    Hu JC, Williams SB, O'Malley AJ, Smith MR, Nguyen PL, Keating NL.
    Eur Urol; 2012 Jun; 61(6):1119-28. PubMed ID: 22336376
    [Abstract] [Full Text] [Related]

  • 4. Risk of Cardiovascular Ischemic Events After Surgical Castration and Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer: A Nationwide Cohort Study.
    Chen DY, See LC, Liu JR, Chuang CK, Pang ST, Hsieh IC, Wen MS, Chen TH, Lin YC, Liaw CC, Hsu CL, Chang JW, Kuo CF, Huang WK.
    J Clin Oncol; 2017 Nov 10; 35(32):3697-3705. PubMed ID: 28968166
    [Abstract] [Full Text] [Related]

  • 5. Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis.
    Guo Z, Huang Y, Gong L, Gan S, Chan FL, Gu C, Xiang S, Wang S.
    Prostate Cancer Prostatic Dis; 2018 Nov 10; 21(4):451-460. PubMed ID: 29988099
    [Abstract] [Full Text] [Related]

  • 6. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
    Keating NL, O'Malley AJ, Smith MR.
    J Clin Oncol; 2006 Sep 20; 24(27):4448-56. PubMed ID: 16983113
    [Abstract] [Full Text] [Related]

  • 7. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer.
    Crawley D, Garmo H, Rudman S, Stattin P, Häggström C, Zethelius B, Holmberg L, Adolfsson J, Van Hemelrijck M.
    Int J Cancer; 2016 Dec 15; 139(12):2698-2704. PubMed ID: 27557616
    [Abstract] [Full Text] [Related]

  • 8. Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events.
    Schmid M, Sammon JD, Reznor G, Kapoor V, Speed JM, Abdollah FA, Sood A, Chun FK, Kibel AS, Menon M, Fisch M, Sun M, Trinh QD.
    BJU Int; 2016 Aug 15; 118(2):221-9. PubMed ID: 26074405
    [Abstract] [Full Text] [Related]

  • 9. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.
    O'Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M.
    J Clin Oncol; 2015 Apr 10; 33(11):1243-51. PubMed ID: 25732167
    [Abstract] [Full Text] [Related]

  • 10. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism.
    Klil-Drori AJ, Yin H, Tagalakis V, Aprikian A, Azoulay L.
    Eur Urol; 2016 Jul 10; 70(1):56-61. PubMed ID: 26138040
    [Abstract] [Full Text] [Related]

  • 11. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.
    Keating NL, O'Malley AJ, Freedland SJ, Smith MR.
    J Natl Cancer Inst; 2010 Jan 06; 102(1):39-46. PubMed ID: 19996060
    [Abstract] [Full Text] [Related]

  • 12. Risk of cardiovascular thrombotic events after surgical castration versus gonadotropin-releasing hormone agonists in Chinese men with prostate cancer.
    Teoh JY, Chan SY, Chiu PK, Poon DM, Cheung HY, Hou SS, Ng CF.
    Asian J Androl; 2015 Jan 06; 17(3):493-6. PubMed ID: 25578930
    [Abstract] [Full Text] [Related]

  • 13. Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapy.
    O'Farrell S, Sandström K, Garmo H, Stattin P, Holmberg L, Adolfsson J, Van Hemelrijck M.
    BJU Int; 2016 Sep 06; 118(3):391-8. PubMed ID: 26497726
    [Abstract] [Full Text] [Related]

  • 14. The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study.
    Gandaglia G, Sun M, Popa I, Schiffmann J, Abdollah F, Trinh QD, Saad F, Graefen M, Briganti A, Montorsi F, Karakiewicz PI.
    BJU Int; 2014 Dec 06; 114(6b):E82-E89. PubMed ID: 24612110
    [Abstract] [Full Text] [Related]

  • 15. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
    Beckmann K, Garmo H, Adolfsson J, Bosco C, Johansson E, Robinson D, Holmberg L, Stattin P, Van Hemelrijck M.
    Eur Urol; 2019 Apr 06; 75(4):676-683. PubMed ID: 30497883
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.
    Wu CT, Yang YH, Chen PC, Chen MF, Chen WC.
    Osteoporos Int; 2015 Sep 06; 26(9):2281-90. PubMed ID: 25990353
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data.
    Scailteux LM, Vincendeau S, Balusson F, Leclercq C, Happe A, Le Nautout B, Polard E, Nowak E, Oger E.
    Eur J Cancer; 2017 May 06; 77():99-108. PubMed ID: 28390298
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.